Expertise in
14
conditions

Monique C. Minnema

Utrecht, UT, NL 
Expertise in
14
conditions
Utrecht, UT, NL 
OverviewLocationsClinical Research

Overview

Monique Minnema practices in Utrecht, Netherlands. Ms. Minnema is highly rated in 14 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Primary Amyloidosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 179 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Utrecht, UT 3584CX, Netherlands
Other Locations
Amsterdam, NH, Netherlands
St. Antonius Hospital
Nieuwegein, UT, Netherlands
Nijmegen, GE, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug
Study Drugs: Daratumumab, Bortezomib Injection, Dexamethasone oral tablet
Study Phase: Phase 2
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Enrollment Status: Active_not_recruiting
Publish Date: January 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

179 Total Publications

The Diagnostic Yield of Cerebrospinal Fluid Analysis for the Diagnosis of Primary Central Nervous System Lymphoma: A Systematic Review.
The Diagnostic Yield of Cerebrospinal Fluid Analysis for the Diagnosis of Primary Central Nervous System Lymphoma: A Systematic Review.
Journal: Cancers
Published: May 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Minnema's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile